These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19234783)

  • 1. Do GnRH analogs protect against ovarian toxicity of chemotherapy?
    Moore HC
    Breast Cancer Res Treat; 2009 Oct; 117(3):569-70. PubMed ID: 19234783
    [No Abstract]   [Full Text] [Related]  

  • 2. Are gonadotropin-releasing hormone analogs safe and effective for protection of ovarian reserve against chemotherapeutic insult?
    Sönmezer M; Taşçi T; Gözüküçük M
    Gynecol Endocrinol; 2008 Feb; 24(2):64-5; author reply 66. PubMed ID: 18210327
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy-induced female infertility and protective action of gonadotropin-releasing hormone analogues.
    Imai A; Furui T
    J Obstet Gynaecol; 2007 Jan; 27(1):20-4. PubMed ID: 17365452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.
    Blumenfeld Z; von Wolff M
    Hum Reprod Update; 2008; 14(6):543-52. PubMed ID: 18824495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.
    Oktay K; Sönmezer M; Oktem O; Fox K; Emons G; Bang H
    Oncologist; 2007 Sep; 12(9):1055-66. PubMed ID: 17914075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
    Blumenfeld Z
    Oncologist; 2007 Sep; 12(9):1044-54. PubMed ID: 17914074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy.
    Blumenfeld Z
    Minerva Endocrinol; 2007 Mar; 32(1):23-34. PubMed ID: 17353864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GnRH analogue for chemotherapy-induced ovarian damage: too early to say?
    Peccatori F; Demeestere I
    Fertil Steril; 2009 Aug; 92(2):e33; author reply e34. PubMed ID: 19646600
    [No Abstract]   [Full Text] [Related]  

  • 9. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data.
    Beck-Fruchter R; Weiss A; Shalev E
    Hum Reprod Update; 2008; 14(6):553-61. PubMed ID: 18820006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of gonadal damage during cytotoxic therapy.
    Blumenfeld Z; Haim N
    Ann Med; 1997 Jun; 29(3):199-206. PubMed ID: 9240625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effect of a gonadotropin-releasing hormone analogue on chemotherapeutic agent-induced ovarian gonadotoxicity: a mouse model.
    Tan SJ; Yeh YC; Shang WJ; Wu GJ; Liu JY; Chen CH
    Eur J Obstet Gynecol Reprod Biol; 2010 Apr; 149(2):182-5. PubMed ID: 20074846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent treatment with gonadotropin-releasing hormone agonists for chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a meta-analysis of randomized controlled trials.
    Yang B; Shi W; Yang J; Liu H; Zhao H; Li X; Jiao S
    Breast; 2013 Apr; 22(2):150-157. PubMed ID: 23298851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Ovarian function does not equal fertility does not equal babies.
    Moore HC; Theriault RL
    Oncologist; 2007 Sep; 12(9):1067-9. PubMed ID: 17914076
    [No Abstract]   [Full Text] [Related]  

  • 14. A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.
    Whitehead J; Toledo MG; Stern CJ
    Aust N Z J Obstet Gynaecol; 2011 Oct; 51(5):452-4. PubMed ID: 21810087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of hormonal protection for chemotherapy-induced gonadotoxicity.
    Kim SS; Lee JR; Jee BC; Suh CS; Kim SH; Ting A; Petroff B
    Clin Obstet Gynecol; 2010 Dec; 53(4):740-52. PubMed ID: 21048441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
    Kim HJ; Lee MH; Lee JE; Park S; Lee ES; Kang YJ; Shin HN; Kim SI; Lee JH; Im SA; Ahn SH; Lee KS; Sohn J; Kim S; Nam SJ; Han W
    Clin Breast Cancer; 2018 Oct; 18(5):e1165-e1172. PubMed ID: 29843988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of gonadotropin releasing hormone analogues for ovarian protection in systemic lupus erythematosus patients treated with cyclophosphamide].
    Liang LQ; Qiu Q; Yang XY; Xu HS; Ye YJ; Zhan ZP; Lian F; Chen DY
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1009-11. PubMed ID: 18754430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
    Elgindy E; Sibai H; Abdelghani A; Mostafa M
    Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should gonadotropin releasing hormone analogue be administered to prevent premature ovarian failure in young women with systemic lupus erythematosus on cyclophosphamide therapy?
    Sinha R; Dionne JM
    Arch Dis Child; 2008 May; 93(5):444-5. PubMed ID: 17908713
    [No Abstract]   [Full Text] [Related]  

  • 20. Preservation of ovarian function during chemotherapy.
    Med Lett Drugs Ther; 2010 Jun; 52(1341):49-50. PubMed ID: 20585283
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.